There is little doubt that vitamin D deficiency across all age groups in Europe is a problem. Low vitamin D status arises due to limited, if any, dermal synthesis during the winter months at latitudes above 408N, putting increased importance on dietary supply of the vitamin. However, dietary intakes by most populations are low due to the limited supply of vitamin D-rich foods in the food chain. Thus strategies that effectively address this public health issue are urgently required. It has been emphasized and re-emphasized that there are only a limited number of public health strategies available to correct low dietary vitamin D intake: (1) improving intake of naturally occurring vitamin D-rich foods, (2) vitamin D fortification (mandatory or voluntarily) of food, and (3) vitamin D supplementation. Recent evidence suggests that the levels of vitamin D added to food would need to be high so as to ensure dietary requirements are met and health outcomes optimized. In addition, knowledge of the most effective forms of vitamin D to use in some of these preventative approaches is important. There is still uncertainty in relation to the relative efficacy of vitamin D 2 versus D 3 , the two main food derived forms and those used in vitamin D supplements. The major metabolite of vitamin D with biological activity is 1,25(OH) 2 D; however, this is usually used for pharmacological purposes and is not typically used in normal, healthy people. The other major metabolite, 25(OH)D, which has also been used for pharmacological purposes is present in certain foods such as meat and meat products (particularly offal) as well as eggs. This metabolite may have the potential to boost vitamin D status up to five times more effectively that native vitamin D 3 in foods. However, the exact bioactivity of this compound needs to be established.
W ithout doubt, vitamin D is the nutrient that has captured the minds and imaginations of the scientific community, authoritative agencies, regulatory bodies, industry, and the public alike in the first decade of the new millennium. It is notable that in the US, the Food and Nutrition Board of the Institute of Medicine (IOM) have very recently released new Dietary Reference Intake (DRI) values for vitamin D (and calcium). The European Food Safety Agency (EFSA) will soon undertake a review of the Population Reference Intake (PRI) values for vitamin D and other micronutrients in Europe. Several EU member states are also re-evaluating their local or regional dietary recommendations for vitamin D.
These activities are not surprising in light of the increasing evidence base during the last decade that potentially links vitamin D to non-skeletal disease (such as cardiovascular disease, diabetes, certain types of cancer, infectious disease, or other autoimmune and inflammatory disease that add greatly to the global burden of disease and total chronic disease deaths) as well as to its more accepted role in metabolic bone disease (rickets, osteomalacia, osteoporosis) risk. An intense research effort has resulted in this increased evidence-base as and has facilitated agencies begin the process of re-evaluation of dietary vitamin D recommendations. However, despite new recommendations, vitamin D deficiency will remain a major public health issue in Europe (and indeed elsewhere), with huge potential cost implications to its health care system and its societies unless effective dietary strategies for prevention of vitamin D deficiency are put in place. The present paper will overview vitamin D deficiency, its prevalence, causes, and health effects, as well as potential dietary strategies for its prevention. In particular it will highlight some existing knowledge gaps in relation to efficacy of different forms of vitamin D that (page number not for citation purpose) would need to be addressed in terms of formulation of effective preventative dietary strategies.
Vitamin D deficiency: a major concern for Europe and the health of its populations There is little doubt that vitamin D deficiency across all age groups in Europe is a problem, the magnitude of which ranges from significant to pandemic depending on which biochemical definition one uses; that is, what level of serum 25- (11, 12) . In addition to its wellaccepted role in these metabolic bone diseases, a large epidemiological, biologically plausible evidence base has increased exponentially during the last decade linking low vitamin D status [serum 25(OH)D B50 nmol/L] with development of non-skeletal diseases (including the cardiometabolic syndrome, diabetes, selected cancers, respiratory infections, autoimmune and inflammatory diseases, and cognitive decline) (13Á15), which collectively make a huge contribution to the global burden of disease and total chronic disease deaths. However, it is worth noting that the evidence basis for some of these outcomes awaits data from randomized clinical trials (RCTs) to prove cause and effect. Currently in the UK, about 40Á55% adolescents (2), 70Á75% of 19Á64-year-old adults (3), and up to 90% of elderly (4) are vitamin D deficient during wintertime using a serum 25(OH)D cutoff of 50 nmol/L. These UK prevalence data are mirrored in other European countries (5Á7). For example, Andersen et al. (5) in their study of adolescent girls and elderly women in four Northern European countries showed that 92% of girls and 67% of women had wintertime serum 25(OH)D below 50 nmol/L. Of note this biochemical cutoff for vitamin D deficiency was accepted recently by the Standing Committee of European Doctors (16) . Some researchers have suggested that serum 25(OH)D levels need to be in excess of 80Á120 nmol/L to optimize health (13, 14) . Most European subjects will have serum 25(OH)D levels below this cutoff in winter and a very high proportion will not reach it even in summer (3, 5Á7).
Why does vitamin D deficiency occur so commonly in Europe?
In humans, vitamin D is obtained primarily through cutaneous biosynthesis in the presence of ultraviolet blue (UVB) sunlight in summer. During wintertime in latitudes greater than 358N, the angle of the sun is too oblique for UVB rays to pass through ozone, so little or no vitamin D is dermally synthesized. The duration of this period during which vitamin D can not be synthesized increases with latitude so, for example, human skin exposed to sunlight on cloudless days in Boston (42.28N) from November through February produced no previtamin D 3 . In Edmonton (528N) this ineffective winter period extended from October through March (17) . There are also many reasons why summertime sun exposure may be inadequate. Improved adherence to public health campaigns to promote sun safety and awareness of the links between excessive sun exposure and skin cancer, as well as premature wrinkles, has led to the widespread use of sunscreen and inclusion of sun protection factor (SPF) ingredients in cosmetic products. Correct application of sunscreen with an SPF of 15 reduces cutaneous skin production of previtamin D 3 by 93% (18) . Dermal synthesis of vitamin D is a much less efficient process in non-Caucasians than in Caucasians and in older than in younger adults. Discreet clothing habits limit sun exposure particularly in veiled women and long working hours spent indoors mean that most adults rely on vacation to spend time outdoors during the day.
In the absence of sufficient UVB for dermal synthesis, vitamin D becomes an essential nutrient; however, food sources of vitamin D are few and the typical average vitamin D intakes in populations within the EU are generally around 2Á5 mg/d (19) . There is a significant gap between typical intakes in European populations and the current dietary targets (10 and 15 mg/d for 1Á70 years; 10 and 20 mg/d for !70 years; US Estimated Average Requirement and Recommended Dietary Allowance values, respectively (8)). Even these new DRI values are not as high as those proposed by some researchers (22) . For example, data from nationally representative surveys shows that 74% of adults in the UK and Ireland are not reaching an intake of 5 mg/d and 90% of older men and women in Ireland are not reaching 10 mg/d (20, 21) . The European dietary recommendation (PRI) for vitamin D for adults also reveals considerable uncertainty about the available evidence on which to base a recommended intake, as it ranges from 0 to 10 mg/d to account not only for the knowledge gaps but also for the widely varying latitudes that EU citizens live in (35Á708N), assuming a higher dietary requirement in more northerly latitudes but not having data to base a requirement on (23) . Two recent controlled, randomized, double-blind vitamin D 3 intervention trials, the first in 245 adults aged 20Á40 years (24) and the second in 225 communitydwelling adults over 64 years (25) Of particular concern, these new target values (even the lowest ones) are considerably beyond current intakes in adolescent (2, 27) and adult populations (in some cases even the high consumers (reflected by those in the 95 percentile of intake) have vitamin D intakes below 9 mg/d (19) . As an example, 84Á97% of adolescents (2) and 93% of adults (20) in the UK National Diet and Nutrition Survey do not reach an intake of 5 and 9 mg/d, respectively.
Addressing the low intake and associated vitamin D deficiency As mentioned already, in humans, vitamin D is obtained primarily through cutaneous biosynthesis in the presence of UVB sunlight in summer. While stores established during summer sun exposure can help reduce the requirement for dietary vitamin D in wintertime, it does not negate this (24, 25) . In addition, it is worth noting that population levels of unprotected summer sun exposure may be rapidly declining, as a consequence of public education campaigns in relation to skin cancer (28) . Thus, dietary supply of vitamin D is taking on increasing importance not only in winter months but potentially also in summer; however, dietary supply is low for most European populations. It has been emphasized and re-emphasized that there are only a limited number of public health strategies available to correct low dietary vitamin D intake:
1. Improving intake of naturally occurring vitamin D-rich foods. However, this is the least likely strategy to counteract low dietary vitamin D intake due to the fact that there are very few food sources that are rich in vitamin D. Furthermore, most of these are not frequently consumed by many in the population (21 (20) , overall intakes are low so these contributions while proportionally high are quantitatively low. This is a function mainly of the relatively low vitamin D content of most supplements in some countries relative to requirement as discussed above. Some are of the view that while not highly effective at a population level, vitamin D supplementation may be appropriate in high risk groups such as the elderly (16, 34, 35) .
Forms of vitamin D and relative efficacy in improving status
While recent evidence suggests that the levels of vitamin D added to food and/or supplements would need to be high so as to ensure dietary requirements are met and health outcomes optimized, knowledge of which are the most effective forms of vitamin D to use in some of these preventative approaches is also important. Houghton and Vieth (39) (39) . While the findings from the above studies and possible underlying mechanisms might suggest so, the case for greater bioefficacy of vitamin D 3 over vitamin D 2 is less than clear. Rapuri et al. (40) reported that in a study of elderly women (mean age, 72 years) who self-reported their use of vitamin D 2 and D 3 supplements, the mean serum total 25(OH)D levels (via competitive protein binding assay) were higher in women on vitamin D 2 (33.692.1 ng/ mL) and vitamin D 3 (29.791.8 ng/mL) supplements (mean dose, 401 and 465 IU/d, respectively) compared to unsupplemented women (27.390.7 ng/mL) during wintertime. In fact, the difference was only significant for those on vitamin D 2 . Holick et al. (41) showed that elevations in serum total 25(OH)D concentrations (via liquid chromatography tandem mass spectroscopy) were identical between healthy adult men and women (n068; mean age, 38. It is clear that the data are ambiguous and may stem from the fact that the various studies that have compared the two forms of vitamin D have had differences in design (season in which study conducted, age profile of subjects), dose/mode of administration of vitamin D, preparation of vitamin D, as well as method of analysis of serum 25(OH)D, all of which may have contributed to the mixed findings and limit a firm conclusion being drawn at this time.
Vitamin D metabolites
The major metabolite of vitamin D with biological activity is 1,25(OH) 2 D; however, this is usually used for pharmacological purposes and is not typically used in normal healthy people. The presence of minor amounts of this metabolite in some foods of animal origin (as is the case with 25(OH)D; see below) and its contribution to biological vitamin D activity has not been investigated.
It has been suggested that the other major metabolite, 25(OH)D, which has also been used for pharmacological purposes, may contribute to vitamin D nutriture. This metabolite is present in certain foods of animal origin. Meat, eggs, and to a lesser extent fish have been shown to possess 25(OH)D (44Á47). There has been some limited investigation of offal (and in particular liver and kidney), which shows that they contain higher amounts of the metabolite than cuts of meat (which is not surprising as these tissues are where vitamin D is metabolized in vivo) (48, 49) . Meat and meat products as well as egg and egg dishes can make sizeable contributions to the mean daily intake of vitamin D for some populations (20, 21) . However, some of this contribution stems from the fact that the UK there is as yet no consensus on the conversion factor that should be used for 25(OH)D to calculate vitamin D activity. Depending on the testing system used, the factor varies from 1.5 to 5 (48) . Moreover, Jakobsen et al. (53) recently showed in a 12-week pig feeding trial that in relation to benefits for human nutrition, 25(OH)D in pig feed should be regarded as lower than vitamin D 3 , as meat and liver produced by feeding the pigs exclusively 25(OH)D had a significantly low content of vitamin D 3 . Priority needs to be given to data from human studies that have experimentally examined this relative potency. Using data from a 1-year intervention study by Rossini et al. (54) in osteopenic/osteoporotic women with hypovitaminosis D, it can be estimated that vitamin D 3 
